{
    "clinical_study": {
        "@rank": "23335", 
        "arm_group": [
            {
                "arm_group_label": "QNASL nasal spray", 
                "arm_group_type": "Active Comparator", 
                "description": "QNASL 320 mcg once-daily administered as two sprays in each nostril; 2 weeks of treatment"
            }, 
            {
                "arm_group_label": "Placebo nasal spray", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo nasal spray once-daily administered as two sprays in each nostril; 2 weeks of treatment"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators hypothesize that treatment with QNASL will reduce nasal mucosal\n      inflammation induced by the allergy season and prevent the changes in the microbiome caused\n      by the allergy season."
        }, 
        "brief_title": "Allergic Rhinitis Changes the Sinus Microbiome", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Seasonal Allergic Rhinitis", 
        "condition_browse": {
            "mesh_term": [
                "Rhinitis, Allergic, Seasonal", 
                "Rhinitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Males and females between 18 and 55 years of age.\n\n          2. Two year history of seasonal allergic rhinitis.\n\n          3. Positive skin test to grass and/or tree antigen.\n\n        Exclusion Criteria:\n\n          1. Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.\n\n          2. Pregnant or lactating women.\n\n          3. Subjects treated with systemic steroids during the previous 30 days.\n\n          4. Subjects treated with topical (inhaled, intranasal or intraocular) steroids,\n             Nasalcrom or Opticrom during the previous 30 days.\n\n          5. Subjects treated with oral antihistamine/decongestants during the previous seven\n             days.\n\n          6. Subjects treated with topical (intranasal or intraocular) antihistamine/decongestants\n             during the previous 3 days.\n\n          7. Subjects treated with immunotherapy and are escalating their dose.\n\n          8. Subjects on chronic anti-asthma medications.\n\n          9. Subjects with polyps in the nose or a significantly displaced septum.\n\n         10. Upper respiratory infection within 14 days prior to study start."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01852513", 
            "org_study_id": "IRB 12-1812"
        }, 
        "intervention": [
            {
                "arm_group_label": "QNASL nasal spray", 
                "intervention_name": "QNASL", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo nasal spray", 
                "intervention_name": "Placebo nasal spray", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chicago", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60637"
                }, 
                "name": "University of Chicago"
            }, 
            "investigator": {
                "last_name": "Robert Naclerio, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Allergic Rhinitis Changes the Sinus Microbiome", 
        "other_outcome": [
            {
                "description": "Quality of life will be assessed with the self-administered rhinoconjunctivitis quality-of-life questionnaire (RQLQ) as described and validated by Juniper and colleagues.", 
                "measure": "Rhinoconjunctivitis quality-of-life questionnaire (RQLQ)", 
                "safety_issue": "No", 
                "time_frame": "Following 2 weeks of treatment with study drug or placebo"
            }, 
            {
                "description": "Total counts of eosinophils recovered from lavages prior to and following treatment", 
                "measure": "Nasal eosinophilia", 
                "safety_issue": "No", 
                "time_frame": "Following 2 weeks of treatment with study drug or placebo"
            }
        ], 
        "overall_contact": {
            "email": "jlane@surgery.bsd.uchicago.edu", 
            "last_name": "James Lane, BS", 
            "phone": "773-702-5889"
        }, 
        "overall_official": {
            "affiliation": "University of Chicago", 
            "last_name": "Robert Naclerio, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Sinonasal microbiome will be examined prior to allergy season and 2 weeks after treatment with QNASL or placebo in the allergy season", 
            "measure": "Change in sinonasal microbiome during the seasonal allergy exposure", 
            "safety_issue": "No", 
            "time_frame": "2 weeks following treatment in the allergy season"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01852513"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Chicago", 
            "investigator_full_name": "Robert Naclerio", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Symptom scores will be recorded by subjects twice daily during the trial.  Subjects report four symptoms: sneezing, rhinorrhea, nasal congestion, and nasal itching on a scale from 0 to 3 (0= no symptoms, 1= mild symptoms, 2= moderate symptoms, 3= severe symptoms).", 
            "measure": "Symptoms of sneezing, rhinitis, nasal congestion and nasal itching", 
            "safety_issue": "No", 
            "time_frame": "2 weeks"
        }, 
        "source": "University of Chicago", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Chicago", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}